Circulation journal : official journal of the Japanese Circulation Society · 2005
Three-year follow-up results of angiographic intervention trial using an HMG-CoA reductase inhibitor to evaluate retardation of obstructive multiple atheroma (ATHEROMA) study.
Клиническое исследованиеСтатьяМногоцентровое исследованиеРандомизированное исследованиеПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yokoi Hiroyoshi, Nobuyoshi Masakiyo, Mitsudo Kazuaki, Kawaguchi Akito, Yamamoto Akira, ATHEROMA Study Investigators
Аннотация
BACKGROUND: The cardiovascular event rate in Japanese populations is strikingly lower than that in Caucasian populations and it has been postulated that this difference might be because of variations in atherosclerosis progression in patients with coronary artery disease (CAD). However, the rate of angiographically assessed progression and its response to statins has not been well described in Japanese patients.
METHODS AND RESULTS: The angiographic intervention trial using an HMG-CoA reductase inhibitor to evaluate the retardation of obstructive multiple atheroma (ATHEROMA) study was a multicenter, randomized, controlled clinical trial investigating the effects of pravastatin on coronary atherosclerosis in Japanese patients with CAD using quantitative coronary angiography. In total, 361 patients with mild to moderate elevated serum total cholesterol concentrations (195-265 mg/dl) received diet only (n = 179) or diet plus pravastatin 10-20 mg/dl (n = 182). Over 3 years, low-density lipoprotein-cholesterol in the pravastatin group decreased by 19.5% (p < 0.0001). A per-patient analysis showed that minimum lumen diameter increased by 0.034+/-0.17 mm in the pravastatin group, but decreased by 0.006+/-0.16 mm in the diet only group (p = 0.04). The mean difference between the treatment groups was 0.040 mm (95% confidence interval 0.020, 0.070 mm).
CONCLUSION: The ATHEROMA study indicates that pravastatin 10-20 mg/day for 3 years improves hyperlipidemia, then suppresses progression and induces regression of focal coronary atherosclerosis in Japanese CAD patients with elevated serum cholesterol.
METHODS AND RESULTS: The angiographic intervention trial using an HMG-CoA reductase inhibitor to evaluate the retardation of obstructive multiple atheroma (ATHEROMA) study was a multicenter, randomized, controlled clinical trial investigating the effects of pravastatin on coronary atherosclerosis in Japanese patients with CAD using quantitative coronary angiography. In total, 361 patients with mild to moderate elevated serum total cholesterol concentrations (195-265 mg/dl) received diet only (n = 179) or diet plus pravastatin 10-20 mg/dl (n = 182). Over 3 years, low-density lipoprotein-cholesterol in the pravastatin group decreased by 19.5% (p < 0.0001). A per-patient analysis showed that minimum lumen diameter increased by 0.034+/-0.17 mm in the pravastatin group, but decreased by 0.006+/-0.16 mm in the diet only group (p = 0.04). The mean difference between the treatment groups was 0.040 mm (95% confidence interval 0.020, 0.070 mm).
CONCLUSION: The ATHEROMA study indicates that pravastatin 10-20 mg/day for 3 years improves hyperlipidemia, then suppresses progression and induces regression of focal coronary atherosclerosis in Japanese CAD patients with elevated serum cholesterol.